| General Information | |
|---|---|
| ZINC ID | ZINC000040935181 |
| Molecular Weight (Da) | 478 |
| SMILES | Cc1c(-c2nnc(C(C)(C)C)s2)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Cl)cc1 |
| Molecular Formula | C22Cl3N4S1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 126.433 |
| HBA | 3 |
| HBD | 0 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 30 |
| LogP | 7.611 |
| Activity (Ki) in nM | 20.4174 |
| Polar Surface Area (PSA) | 71.84 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.997 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 22 |
| Fraction csp3 | 0.23 |
| Ilogp | 4.69 |
| Xlogp3 | 7.47 |
| Wlogp | 7.62 |
| Mlogp | 5.26 |
| Silicos-it log p | 7.8 |
| Consensus log p | 6.57 |
| Esol log s | -7.79 |
| Esol solubility (mg/ml) | 0.0000078 |
| Esol solubility (mol/l) | 1.63E-08 |
| Esol class | Poorly sol |
| Ali log s | -8.81 |
| Ali solubility (mg/ml) | 0.00000073 |
| Ali solubility (mol/l) | 1.54E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.78 |
| Silicos-it solubility (mg/ml) | 7.99E-08 |
| Silicos-it solubility (mol/l) | 1.67E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.91 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.94 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.939 |
| Logd | 5.439 |
| Logp | 6.594 |
| F (20%) | 0.002 |
| F (30%) | 0.479 |
| Mdck | - |
| Ppb | 100.17% |
| Vdss | 2.284 |
| Fu | 2.19% |
| Cyp1a2-inh | 0.485 |
| Cyp1a2-sub | 0.831 |
| Cyp2c19-inh | 0.762 |
| Cyp2c19-sub | 0.216 |
| Cl | 1.218 |
| T12 | 0.019 |
| H-ht | 0.243 |
| Dili | 0.943 |
| Roa | 0.257 |
| Fdamdd | 0.9 |
| Skinsen | 0.021 |
| Ec | 0.003 |
| Ei | 0.029 |
| Respiratory | 0.073 |
| Bcf | 3.64 |
| Igc50 | 5.022 |
| Lc50 | 6.167 |
| Lc50dm | 5.906 |
| Nr-ar | 0.188 |
| Nr-ar-lbd | 0.528 |
| Nr-ahr | 0.241 |
| Nr-aromatase | 0.94 |
| Nr-er | 0.938 |
| Nr-er-lbd | 0.593 |
| Nr-ppar-gamma | 0.394 |
| Sr-are | 0.96 |
| Sr-atad5 | 0.364 |
| Sr-hse | 0.076 |
| Sr-mmp | 0.958 |
| Sr-p53 | 0.86 |
| Vol | 436.607 |
| Dense | 1.09 |
| Flex | 0.182 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 3 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.305 |
| Synth | 2.66 |
| Fsp3 | 0.227 |
| Mce-18 | 26 |
| Natural product-likeness | -1.502 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |